Johnson & Johnson Stock Holds Above Dividend Level as Sales Guidance Climbs

Johnson & Johnson's (JNJ) stock continues to hold its value above its dividend level, trading in the low $270s as of August 23, 2026. The company's market capitalization is reported at $651.38 billion and its price-to-earnings ratio is 31.32.

The pharmaceutical and medtech giant has raised its full-year 2026 sales guidance to a midpoint of $101.1 billion, signaling that it expects to cross the $100 billion annual revenue threshold for the first time this year. Adjusted earnings per share guidance was also lifted by $0.13 to $11.68.

The company's innovative medicines segment continues to grow, with sales rising 7.8 percent year over year to $16.38 billion in the latest reported quarter. This growth is expected to help Johnson & Johnson sustain its dividend payments and fund litigation settlements and investments in new products.